BridgeMD
New treatment option for Psoriasis
Official title Genetic Variation in TRAF3IP2 (rs13190932)
ClinicalTrials.gov ID: NCT07086924
What this study is testing
What is Methotrexate?
Methotrexate is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for psoriasis.
Also referred to as Genetic variation in TRAF3IP2.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population. It is characterized by red, scaly plaques that can appear on various parts of the body, causing significant physical and psychological burden to affected individuals.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70. Healthy volunteers may be eligible.
You may be able to join if
- Patients aged 18 -70years .
- the severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI \> 12 (severe severity)...
- Willingness to participate: Signed informed consent.
- Initiating methotrexate (MTX) therapy: For prospective cohort.
- Availability for follow-up: Patients must be willing and able to attend scheduled visit.
You likely can't join if
- Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus).
- Pregnancy and lactation.
- Patients currently undergoing immunosuppressive or systemic therapies.
- Patients with known genetic disorders affect immune system function.
- Patients with liver or kidney impairment.
- Patients with allergy or contraindication to methotrexate.
See the full eligibility criteria
- Patients aged 18 -70years .
- the severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI \> 12 (severe severity). (15)Confirmed diagnosis: Psoriasis vulgaris (PsV) or psoriatic arthritis...
- Willingness to participate: Signed informed consent.
- Initiating methotrexate (MTX) therapy: For prospective cohort.
- Availability for follow-up: Patients must be willing and able to attend scheduled visit.
- Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus).
- Pregnancy and lactation.
- Patients currently undergoing immunosuppressive or systemic therapies.
- Patients with known genetic disorders affect immune system function.
- Patients with liver or kidney impairment.
- Patients with allergy or contraindication to methotrexate.
- Patients with active or uncontrolled infections, including chronic infections like tuberculosis.
- Previous genetic analysis Patients who have previously undergone genetic analysis for the TRAF3IP2 gene polymorphism (rs13190932).
The study team makes the final eligibility decision.
Where it's taking place
- Qina, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Qina, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.